PDL's Buyout of ESP Pharma: $475 Million for Drugs, Sales Team

Protein Design Labs has agreed to buy the hospital-focused pharmaceutical firm ESP Pharma for $300 million in cash and roughly $175 million in stock, thereby gaining marketed products, a 75-person sales force, entry into the cardiac field -- and approximately $14 million in ESP debt.

BioWorld (http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=34564)